The article, titled ”Characterization of a manganese-containing nanoparticle as MRI contrast agent”, is the result of a collaboration with researchers at the University of Turin led by professor Silvio Aime. The paper describes physicochemical studies where the signal strength of SpagoPix has been documented.
”We have shown that, overall, the per-manganese relaxivity of SpagoPix is among the highest reported for manganese-containing systems and far higher than those of the clinically used gadolinium based contrast agents”, the authors state.
The article is available at https://onlinelibrary.wiley.com/journal/10990682c.
Spago Nanomedical is currently preparing SpagoPix for clinical studies, starting in breast cancer patients.
For further information, contact Mats Hansen, VD Spago Nanomedical AB, +46 46 81188, email@example.com.